The next generation biopharmaceuticals

Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma

2014-11-27

Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma

Oslo, Norway and Solna, Sweden – Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies (RIT) for multiple myeloma.

Backed by a Eurostars grant the project will combine Affibody’s proprietary platforms with Nordic Nanovector’s radioimmunotherapy technology. The project aims to provide documentation necessary to start GMP manufacturing of the Affibody®-based RIT and subsequently start clinical trials. The companies have been awarded approximately €1m in total by Vinnova in Sweden and The Norwegian Research Council in Norway.

Upon a successful conclusion of the collaboration Nordic Nanovector will have the opportunity to license the global rights to the Affibody®-based RIT. The development of an Affibody®-based RIT treatment represents a distinct work stream to be carried out in parallel with Nordic Nanvector’s lead product candidate Betalutin™ for non-Hodgkin Lymphoma treatment.

Luigi Costa, Nordic Nanovector CEO commented, “The collaboration with Affibody will allow Nordic Nanovector to expand its product pipeline, while at the same time retaining full focus on the clinical development and commercialization of our lead product candidate, Betalutin™. This collaboration serves as an example of how the company intends to leverage its proprietary targeting technology to treat other hematological cancers in need of novel therapeutic approaches.“

David Bejker, Affibody CEO commented, ”We are delighted to enter into this agreement with Nordic Nanovector and see RIT’s as an area with great potential and a logical continuation of some of our research. The Eurostars platform offers an excellent way for two companies with complementary technologies to collaborate and bring novel therapeutics to market and for Affibody, this comes on top of a year of increased uptake for our platform.”

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report Q2 (August 23, 2018)